Aquestive Therapeutics, Inc. (AQST) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $4.18 (+2.07%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 6, 2024 | Thomas Flaten | Loop Capital Markets | $10.00 | +138.9% |
| Jun 25, 2024 | Thomas Flaten | Loop Capital Markets | $7.00 | +67.3% |
| Apr 11, 2024 | David Amsellem | Piper Sandler | $10.00 | +138.9% |
| Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $9.00 | +115.1% |
| Mar 15, 2024 | Francois Brisebois | Oppenheimer | $12.00 | +186.7% |
Top Analysts Covering AQST
AQST vs Sector & Market
| Metric | AQST | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +115.0% | +1150.1% | +14.9% |
| P/E Ratio | -5.95 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $11M | $12M | $12M | 7 |
| 2026-09-30 | $12M | $13M | $13M | 4 |
| 2026-12-31 | $12M | $13M | $14M | 4 |
| 2027-03-31 | $13M | $14M | $15M | 4 |
| 2027-06-30 | $15M | $16M | $17M | 3 |
| 2027-09-30 | $18M | $20M | $21M | 3 |
| 2027-12-31 | $21M | $23M | $25M | 3 |
| 2028-12-31 | $93M | $110M | $139M | 4 |
| 2029-12-31 | $158M | $186M | $236M | 3 |
| 2030-12-31 | $295M | $347M | $440M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.13 | $-0.11 | $-0.09 | 3 |
| 2026-09-30 | $-0.12 | $-0.11 | $-0.10 | 1 |
| 2026-12-31 | $-0.12 | $-0.11 | $-0.10 | 1 |
| 2027-03-31 | $-0.12 | $-0.11 | $-0.10 | 1 |
| 2027-06-30 | $-0.11 | $-0.10 | $-0.09 | 1 |
| 2027-09-30 | $-0.10 | $-0.09 | $-0.08 | 1 |
| 2027-12-31 | $-0.08 | $-0.07 | $-0.07 | 1 |
| 2028-12-31 | $-0.46 | $-0.26 | $0.10 | 3 |
| 2029-12-31 | $0.06 | $0.07 | $0.10 | 1 |
| 2030-12-31 | $0.53 | $0.66 | $0.89 | 1 |
Frequently Asked Questions
What is the analyst consensus for AQST?
The consensus among 1 analysts covering Aquestive Therapeutics, Inc. (AQST) is Buy with an average price target of $10.00.
What is the highest price target for AQST?
The highest price target for AQST is $12.00, set by Francois Brisebois at Oppenheimer on 2024-03-15.
What is the lowest price target for AQST?
The lowest price target for AQST is $7.00, set by Thomas Flaten at Loop Capital Markets on 2024-06-25.
How many analysts cover AQST?
1 analysts have issued ratings for Aquestive Therapeutics, Inc. in the past 12 months.
Is AQST a buy or sell right now?
Based on 1 analyst ratings, AQST has a consensus rating of Buy (2.00/5) with a +115.0% upside to the consensus target of $10.00.
What are the earnings estimates for AQST?
Analysts estimate AQST will report EPS of $-0.11 for the period ending 2026-06-30, with revenue estimated at $12M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.